Infection prevention products manufacturer Tristel (TSTL) has announced results for its half-year ended 31st December 2022 emphasising “achieving 16% revenue growth and a 16-fold increase in EBITDA”. So what of the shares currently up to 330p, but still down from when I previously concluded bearishly a year ago?